AU Patent

AU2006222060B2 — Roflumilast for the treatment of diabetes mellitus

Assigned to Takeda GmbH · Expires 2011-09-01 · 15y expired

What this patent protects

The invention relates to the use of Roflumilast and/or Roflumilast-N-Oxide for the treatment of diabetes mellitus and accompanying disorders thereof. The invention additionally relates to combinations of Roflumilast and/or Roflumilast-N-Oxide with other active agents for the trea…

USPTO Abstract

The invention relates to the use of Roflumilast and/or Roflumilast-N-Oxide for the treatment of diabetes mellitus and accompanying disorders thereof. The invention additionally relates to combinations of Roflumilast and/or Roflumilast-N-Oxide with other active agents for the treatment of diabetes mellitus.

Drugs covered by this patent

Patent Metadata

Patent number
AU2006222060B2
Jurisdiction
AU
Classification
—
Expires
2011-09-01
Drug substance claim
No
Drug product claim
No
Assignee
Takeda GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.